Aurion Biotech to Present at the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) and Ophthalmology European Futures Forum

SEATTLE & CAMBRIDGE, Mass. & TOKYO -- Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it will present clinical data on its allogeneic cell therapy drug candidate, AURN001, at the 42 nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS 2024) to be held September 6-10, 2024 in Barcelona, Spain. Aurion Biotech also will present and participate in several panel discussions during the Ophthalmology Futures European Forum, which takes place September 5th in Barcelona. Read More

Aurion Biotech to Present at the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) and Ophthalmology European Futures Forum

Aurion Biotech to Present at the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) and Ophthalmology European Futures Forum

Aurion Biotech to Present at the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) and Ophthalmology European Futures Forum

Aurion Biotech to Present at the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) and Ophthalmology European Futures Forum

Aurion Biotech to Present at the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) and Ophthalmology European Futures Forum